Novavax Inc (NASDAQ:NVAX)
| 135.30 Delayed Data As of 5:41pm ET |  +0.74 / +0.55%Today’s Change | 76.59 Today|||52-Week Range 331.68 | +21.33% Year-to-Date |
Latest NVAX News | Press Releases
Today’s Trading
| Previous close | 134.56 |
| Today’s open | 133.10 |
| Day’s range | 130.88 - 135.92 |
| Volume | 97,674 |
| Average volume (3 months) | 5,032,478 |
| Market cap | $10.0B |
Data as of 5:41pm ET, 10/25/2021
Growth & Valuation
| Earnings growth (last year) | -31.99% |
| Earnings growth (this year) | -15.08% |
| Earnings growth (next 5 years) | +2.00% |
| Revenue growth (last year) | +2,448.48% |
| P/E ratio | NM |
| Price/Sales | 13.49 |
| Price/Book | 15.19 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| NBIXNeurocrine Bioscienc... | -1.11 | -1.07% |
| NTLAIntellia Therapeutic... | +1.78 | +1.35% |
| ZLABZai Lab Ltd | +3.17 | +3.15% |
| XLRNAcceleron Pharma Inc | -0.31 | -0.18% |
Data as of 4:00pm ET, 10/25/2021
Financials
| Next reporting date | November 5, 2021 |
| EPS forecast (this quarter) | -$3.91 |
| Annual revenue (last year) | $475.6M |
| Annual profit (last year) | -$418.3M |
| Net profit margin | -87.94% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Gaithersburg, Maryland |
Forecasts
